icon-email icon-facebook icon-linkedin icon-print icon-rss icon-search icon-stumbleupon icon-twitter icon-arrow-right icon-email icon-facebook icon-linkedin icon-print icon-rss icon-search icon-stumbleupon icon-twitter icon-arrow-right icon-user Skip to content

Money

Nektar Therapeutics bumps along ahead of August FDA action on new non-addictive opioid

Shares of Nektar Therapeutics (NKTR) have been bumping along between $32 and $34 for two months now, but the company continues to take steps to prepare for the likely August approval of NKTR-181, a new non-addictive opioid. Nektar has formed Inheris Biopharma, a wholly-owned subsidiary of Nektar, to handle the launch preparation and commercialization of NKTR-181, the first opioid molecule designed to provide the extremely effective pain relief of an opioid without the high levels of euphoria of existing opioids that lead to addiction. NKTR is currently under review at the U.S. Food & Drug Administration with an FDA advisory panel meeting in early August ahead of an August 29 hearing that I expect to result in approval for the new drug.

Ways to Vet a Caregiver or Caregiving Agency

Recently, The Wall Street Journal published the results of its investigation into the practices of Care.com, the country’s largest matching site for caregivers, babysitters and nannies. What it found raises serious questions for anyone who needs to hire help to care for a loved one. Care.com claims to have overhauled many questionable procedures and policies…

The post Ways to Vet a Caregiver or Caregiving Agency appeared first on Next Avenue.

Latest Stories

Choosing Senior Living
Choosing Senior Living
Love Old Journalists

Our Mission

To amplify the voices of older adults for the good of society

Learn More

News & Opinion from Senior Correspondents Across the Globe